Cronos Group Inc.
Cronos Group Inc. (CRON) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · CRON · as of Jun 8, 2026
Key Statistics
Explore Cronos Group Inc. Data
cron stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 15 · Buy rate: 20.0%
The CRON analyst consensus is Hold, based on ratings from 15 Wall Street analysts over the past 3 months. The average 12-month price target is $2.30, representing -16.97% downside from the current price of $2.77.
Competitors & Peers
cron competitorsCRON
AMPH
BBOT
COLL
EMBC
IRMDStock Performance
Full HistoryAbout Cronos Group Inc.
Cronos Group Inc. is a company primarily focused on cannabinoids. In the United States, it develops, promotes, and supplies hemp-derived wellness and beauty products under the Lord Jones and Happy Dan…
what is cronos group inc. · cron stock overview · cronos group inc. company profile · who is cronos group inc. ceo · cron NASDAQ · cronos group inc. headquarters · cronos group inc. business segments
About Stock Overview & Key Data
Cronos Group Inc. (CRON) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry, listed on NASDAQ since Feb 27, 2018. As of the latest trading session, CRON stock price is $2.77, with a market capitalization of $1.0B. The stock has returned +42.09% over the past 12 months and +5.89% year-to-date.
According to 15 Wall Street analysts, the consensus rating for Cronos Group Inc. stock is Hold, with an average 12-month price target of $2.30. In fiscal year 2025, Cronos Group Inc. reported revenue of $193.4M and net income of -$9.4M. For detailed data — including Cronos Group Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Cronos Group Inc. (CRON) stock price is $2.77. The stock is traded on NASDAQ under the ticker symbol CRON. The 52-week range is $1.84 – $3.43.